Cue Biopharma, Inc.
CUE
$0.768
-$0.0004-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -40.67M | -44.61M | -46.96M | -49.97M | -50.73M |
| Total Depreciation and Amortization | 2.35M | 3.29M | 3.42M | 3.36M | 3.44M |
| Total Amortization of Deferred Charges | 37.00K | 37.00K | 37.00K | 37.00K | 37.00K |
| Total Other Non-Cash Items | 6.88M | 7.70M | 8.12M | 8.38M | 8.23M |
| Change in Net Operating Assets | -4.93M | -4.67M | -3.15M | -715.00K | -934.00K |
| Cash from Operations | -36.33M | -38.26M | -38.53M | -38.91M | -39.96M |
| Capital Expenditure | -66.00K | -64.00K | -65.00K | -55.00K | -- |
| Sale of Property, Plant, and Equipment | 98.00K | 97.00K | 0.00 | 0.00 | 2.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 5.00M | 10.00M | 25.00M |
| Cash from Investing | 32.00K | 33.00K | 4.94M | 9.95M | 25.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.00M | -4.00M | -4.00M | -3.00M | -2.00M |
| Issuance of Common Stock | 14.24M | 19.96M | 14.73M | 16.83M | 13.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.24M | 15.96M | 10.73M | 13.83M | 11.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.05M | -22.27M | -22.87M | -15.14M | -3.10M |